Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.
By
/ March 3, 2026
Cookie Consent
We use cookies to improve your experience on our site. By using our site, you consent to cookies. You can read our Privacy Policy.
This website uses cookies
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.
Name
Description
Duration
Service URL
Cookie Preferences
This cookie is used to store the user's cookie consent preferences.
